GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Equity-to-Asset

Progen Co (XKRX:296160) Equity-to-Asset : 0.00 (As of . 20)


View and export this data going back to 2023. Start your Free Trial

What is Progen Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Progen Co's Total Stockholders Equity for the quarter that ended in . 20 was ₩0.00 Mil. Progen Co's Total Assets for the quarter that ended in . 20 was ₩0.00 Mil.

The historical rank and industry rank for Progen Co's Equity-to-Asset or its related term are showing as below:

XKRX:296160's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Progen Co Equity-to-Asset Historical Data

The historical data trend for Progen Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Equity-to-Asset Chart

Progen Co Annual Data
Trend
Equity-to-Asset

Progen Co Semi-Annual Data
Equity-to-Asset

Competitive Comparison of Progen Co's Equity-to-Asset

For the Biotechnology subindustry, Progen Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Progen Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Progen Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Progen Co's Equity-to-Asset falls into.



Progen Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Progen Co's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as

Equity to Asset (A: . 20 )=Total Stockholders Equity/Total Assets
=/
=

Progen Co's Equity to Asset Ratio for the quarter that ended in . 20 is calculated as

Equity to Asset (Q: . 20 )=Total Stockholders Equity/Total Assets
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Progen Co  (XKRX:296160) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Progen Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Progen Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Progen Co Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines